Učitavanje...
Lonafarnib: First Approval
Lonafarnib (Zokinvy™) is an orally active farnesyltransferase inhibitor developed by Eiger BioPharmaceuticals under license from Merck & Co. for the treatment of hepatitis D virus (HDV) infections, and progeria and progeroid laminopathies. The drug was originally discovered by Merck & Co as...
Spremljeno u:
| Izdano u: | Drugs |
|---|---|
| Glavni autor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer International Publishing
2021
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7985116/ https://ncbi.nlm.nih.gov/pubmed/33590450 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-020-01464-z |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|